Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-09-03 00:00:00 ET · period of report 2025-08-29 · accession 0001415889-25-023491 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-03 | 2025-08-29 | LXEO | Tamayo Louis Edward | CFO | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
| D | 2025-09-03 | 2025-08-29 | LXEO | Tamayo Louis Edward | CFO | A - Grant | $0.00 | +280.0K | 280.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-29 | A | A | 45,000 | $0.00 | 45,000 | D | — | — | (F1) The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on August 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. (F2) The reported securities are RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2025-08-29 | A | A | 280,000 | $0.00 | 280,000 | D | $4.79 · — to 2035-08-28 | 280,000 Common Stock | (F3) 25% of the shares underlying the option vest and become exercisable on August 15, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |